Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative drugs operate by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these substances increase insulin release and reduce glucagon secret

The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in t